BenevolentAI Ltd., an artificial intelligence (AI)-driven drug discovery firm that sees the pharmaceutical industry as ripe for disruption, has raised $115 million to scale up its drug development activities, broaden its disease focus and hire new talent. Since 2013, it has raised more than $200 million, including the latest inflow, sourced primarily from U.S. investors.